Immunogen (IMGN) Tops Q3 EPS by 3c, Revenues Beat; Provides FY19 Revenue Guidance Above Consensus
Tweet Send to a Friend
Immunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
